For the year ending 2025-12-31, CDLX had -$16,875K decrease in cash & cash equivalents over the period. $8,810K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -103,488 |
| Credit loss expense | 2,134 |
| Depreciation and amortization | 25,244 |
| Amortization of financing costs charged to interest expense | 1,522 |
| Amortization of right-of-use asset | 2,165 |
| Impairment of goodwill and intangible assets | 58,843 |
| Gain (loss) on disposition of business | 4,831 |
| Gain on debt extinguishment | 0 |
| Stock-based compensation expense | 28,129 |
| Business combination, contingent consideration, change in contingent consideration, liability, increase (decrease) | 102 |
| Other non-cash expense (income), net | 6,243 |
| Accounts receivable and contracts assets, net | -20,643 |
| Prepaid expenses and other assets | -1,803 |
| Accounts payable | 179 |
| Other accrued expenses | -724 |
| Partner share liability | -8,208 |
| Customer incentive liability | -7,980 |
| Net cash provided by (used in) operating activities | 9,290 |
| Acquisition of property and equipment | 480 |
| Capitalized software development costs | 15,302 |
| Proceeds from divestiture of businesses, net of cash divested | 480 |
| Net cash used in investing activities | -15,302 |
| Proceeds from issuance of debt | 56,000 |
| Principal payments of debt | 62,000 |
| Proceeds from termination of capped calls related to convertible notes | 0 |
| Proceeds from issuance of common stock | 0 |
| Settlement of contingent consideration | 5,000 |
| Equity issuance costs | 0 |
| Debt issuance costs | 122 |
| Net cash (used in) provided by financing activities | -11,122 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 259 |
| Net decrease in cash, cash equivalents and restricted cash | -16,875 |
| Cash, cash equivalents, and restricted cash beginning of period | 65,594 |
| Cash, cash equivalents, and restricted cash end of period | 48,719 |
Cardlytics, Inc. (CDLX)
Cardlytics, Inc. (CDLX)